Deep Track Capital, LP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Deep Track Capital, LP reported 67 stock positions worth $3.3 billion. Its top holding was Amgen (AMGN) at 5.4% of the portfolio, followed by Argenx SE - ADR (ARGX, 5.1%) and Axsome Therapeutics (AXSM, 4.5%). Compared with Q1 2024, it opened 10 new positions, sold out of 8, added to 22 and reduced 20. The biggest buy was Immunovant (IMVT, shares +485%) and the biggest sale Apogee Therapeutics (APGE, shares −57%).
- Most Recent 13F
- Q2 2026
- Location
- GREENWICH, CT
- CIK
- 0001856083
- Portfolio Value
- $3.3B (Q2 2024)
- SEC Filing
- 0001856083-24-000003 ↗ filed Aug 14, 2024
Holdings Value
Holdings 67 stocks · $3.3B
| AMGN Amgen Inc. | 5.37% | 575,000 | $179.7M | Add +4.5% |
| ARGX Argenx SE - ADR | 5.14% | 400,000 | $172.0M | Add +33.3% |
| AXSM Axsome Therapeutics Inc. | 4.45% | 1,852,784 | $149.1M | Add +42.0% |
| DYN Dyne Therapeutics Inc. | 4.22% | 4,000,000 | $141.2M | Reduce -12.2% |
| SWTX Springworks Therapeutics Inc. | 4.16% | 3,700,000 | $139.4M | Add +6.3% |
| INSM Insmed Inc. | 4.00% | 2,000,000 | $134.0M | Reduce -58.2% |
| GH Guardant Health Inc. | 3.88% | 4,500,000 | $130.0M | Reduce -25.0% |
| DVAX Dynavax Technologies Corp. | 3.66% | 10,900,000 | $122.4M | Add +19.2% |
| ALNY Alnylam Pharmaceuticals Inc. | 3.63% | 500,000 | $121.5M | Reduce -39.9% |
| NTLA Intellia Therapeutics Inc. | 3.21% | 4,800,000 | $107.4M | Add +14.0% |
| ITCI Intra-Cellular Therapies Inc. | 3.15% | 1,537,922 | $105.3M | Add +2.5% |
| APLS Apellis Pharmaceuticals Inc. | 2.86% | 2,500,000 | $95.9M | Add +150.0% |
| IONS Ionis Pharmaceuticals Inc. | 2.85% | 2,000,000 | $95.3M | Add +45.6% |
| OCUL Ocular Therapeutix Inc. | 2.60% | 12,721,460 | $87.0M | No change |
| FDMT 4D Molecular Therapeutics Inc. | 2.55% | 4,061,401 | $85.2M | Add +33.8% |
| ALKS Alkermes PLC | 2.52% | 3,500,000 | $84.3M | No change |
| NRIX Nurix Therapeutics Inc. | 2.49% | 3,991,500 | $83.3M | Add +33.1% |
| IMVT Immunovant Inc. | 2.27% | 2,883,736 | $76.1M | Add +484.5% |
| BCYC Bicycle Therapeutics PLC-ADR | 2.11% | 3,490,506 | $70.6M | No change |
| PLRX Pliant Therapeutics Inc. | 1.92% | 5,972,257 | $64.2M | Add +3.9% |
| TVTX Travere Therapeutics Inc. | 1.81% | 7,370,000 | $60.6M | No change |
| VRNA Verona Pharma Ltd. | 1.73% | 4,000,000 | $57.8M | Add +25.5% |
| ABVX Abivax SA-ADR | 1.65% | 4,179,763 | $55.3M | Reduce -2.7% |
| GERN Geron Corp. | 1.65% | 13,000,000 | $55.1M | Reduce -57.4% |
| AUTL Autolus Therapeutics PLC | 1.59% | 15,272,172 | $53.1M | No change |
| TGTX TG Therapeutics Inc. | 1.52% | 2,870,131 | $51.1M | New |
| VRDN Viridian Therapeutics Inc. | 1.52% | 3,923,849 | $51.0M | Add +13.5% |
| KYMR Kymera Therapeutics Inc. | 1.34% | 1,500,000 | $44.8M | Add +18.8% |
| MIND MEDICINE MINDMED INC | 1.31% | 6,103,817 | $44.0M | Reduce -8.4% |
| OLMA Olema Pharmaceuticals Inc. | 1.29% | 4,000,000 | $43.3M | Add +24.0% |
| TERN Terns Pharmaceuticals Inc. | 1.24% | 6,100,000 | $41.5M | No change |
| SYRE Spyre Therapeutics Inc. | 1.23% | 1,756,667 | $41.3M | Add +44.8% |
| APGE Apogee Therapeutics Inc. | 1.18% | 1,000,000 | $39.4M | Reduce -57.0% |
| GPCR Structure Therapeutics Inc. | 1.11% | 950,000 | $37.3M | Add +2266.9% |
| ANIP Ani Pharmaceuticals Inc. | 0.89% | 466,089 | $29.7M | Reduce -43.3% |
| EDIT Editas Medicine Inc. | 0.84% | 6,000,000 | $28.0M | Add +8.6% |
| CLYM Climb Bio Inc. filed as ELIEM THERAPEUTICS INC | 0.83% | 3,904,785 | $27.8M | New |
| HLVX Hillevax Inc. | 0.79% | 1,832,652 | $26.5M | Reduce -28.8% |
| KRRO Korro Bio Inc. | 0.78% | 770,645 | $26.1M | New |
| SLN Silence Therapeutics PLC-ADR | 0.77% | 1,359,745 | $25.8M | Reduce -17.3% |
| NKTR Nektar Therapeutics | 0.66% | 17,875,498 | $22.2M | Reduce -2.9% |
| ENGN Engene Holdings Inc. | 0.63% | 2,250,000 | $21.2M | No change |
| ALEC Alector Inc. | 0.63% | 4,631,998 | $21.0M | Add +22.9% |
| ETNB 89BIO Inc. | 0.55% | 2,294,011 | $18.4M | New |
| FATE Fate Therapeutics Inc. | 0.55% | 5,572,607 | $18.3M | No change |
| INO Inovio Pharmaceuticals Inc. | 0.50% | 2,066,720 | $16.7M | New |
| PRAX Praxis Precision Medicines I | 0.48% | 389,546 | $16.1M | New |
| CYBIN INC | 0.47% | 58,139,535 | $15.8M | No change |
| CNTX Context Therapeutics Inc. | 0.44% | 7,419,355 | $14.9M | New |
| PYXS Pyxis Oncology Inc. | 0.41% | 4,184,100 | $13.8M | No change |
| IVVD Invivyd Inc. | 0.36% | 10,953,937 | $12.0M | No change |
| ZURA Zura Bio Ltd. | 0.34% | 3,283,783 | $11.5M | Add +30.1% |
| KURA Kura Oncology Inc. | 0.24% | 384,756 | $7.9M | New |
| CYTK Cytokinetics Inc. | 0.21% | 132,495 | $7.2M | New |
| RGLS Regulus Therapeutics Inc. | 0.17% | 3,262,564 | $5.8M | Reduce -0.1% |
| ANRO Alto Neuroscience Inc. | 0.16% | 511,686 | $5.5M | Reduce -14.7% |
| AGEN Agenus Inc. | 0.16% | 313,359 | $5.2M | Reduce -80.2% |
| ALLK Allakos LLC | 0.15% | 5,000,000 | $5.0M | No change |
| SYRS Syros Pharmaceuticals Inc. | 0.13% | 828,485 | $4.3M | No change |
| RLMD Relmada Therapeutics Inc. | 0.11% | 1,234,773 | $3.7M | Reduce -0.4% |
| EWTX Edgewise Therapeutics Inc. | 0.10% | 186,386 | $3.4M | New |
| SRRK Scholar Rock Holding Corp. | 0.09% | 372,559 | $3.1M | Reduce -45.2% |
| RPTX Repare Therapeutics Inc. | 0.09% | 904,261 | $3.0M | Reduce -66.3% |
| COGT Cogent Biosciences Inc. | 0.08% | 308,235 | $2.6M | Reduce -2.5% |
| VIGL Vigil Neuroscience Inc. | 0.07% | 597,215 | $2.4M | Reduce -62.6% |
| ALGS Aligos Therapeutics Inc. | 0.06% | 6,102,770 | $2.1M | No change |
| MGX Metagenomi Therapeutics Inc. | 0.06% | 466,232 | $1.9M | No change |
Options reported separately and not counted above: NMRA calls ($1.8M).
Portfolio Sells Q1 2024 → Q2 2024
| APGE Apogee Therapeutics Inc. | Reduce -57.0% | 1.18% | −3.26 |
| GERN Geron Corp. | Reduce -57.4% | 1.65% | −1.25 |
| TRML Tourmaline Bio Inc. | Sold out | 0.00% | −1.05 |
| PACB Pacific Biosciences of Calif | Sold out | 0.00% | −0.75 |
| ANIP Ani Pharmaceuticals Inc. | Reduce -43.3% | 0.89% | −0.75 |
| NUVL Nuvalent Inc. Class A | Sold out | 0.00% | −0.59 |
| MIND MEDICINE MINDMED INC | Reduce -8.4% | 1.31% | −0.49 |
| HLVX Hillevax Inc. | Reduce -28.8% | 0.79% | −0.44 |
| NMRA Neumora Therapeutics Inc. | Sold out | 0.00% | −0.40 |
| AGEN Agenus Inc. | Reduce -80.2% | 0.16% | −0.37 |
| ANAB Anaptysbio Inc. | Sold out | 0.00% | −0.34 |
| RPTX Repare Therapeutics Inc. | Reduce -66.3% | 0.09% | −0.27 |
| SRRK Scholar Rock Holding Corp. | Reduce -45.2% | 0.09% | −0.25 |
| SLN Silence Therapeutics PLC-ADR | Reduce -17.3% | 0.77% | −0.25 |
| RARE Ultragenyx Pharmaceutical Inc. | Sold out | 0.00% | −0.23 |
| ABVX Abivax SA-ADR | Reduce -2.7% | 1.65% | −0.12 |
| ANRO Alto Neuroscience Inc. | Reduce -14.7% | 0.16% | −0.10 |
| RGLS Regulus Therapeutics Inc. | Reduce -0.1% | 0.17% | −0.10 |
| VIGL Vigil Neuroscience Inc. | Reduce -62.6% | 0.07% | −0.09 |
| MERSANA THERAPEUTICS INC | Sold out | 0.00% | −0.07 |
| PRME Prime Medicine Inc. | Sold out | 0.00% | −0.06 |
| RLMD Relmada Therapeutics Inc. | Reduce -0.4% | 0.11% | −0.06 |
| COGT Cogent Biosciences Inc. | Reduce -2.5% | 0.08% | +0.02 |
| ALNY Alnylam Pharmaceuticals Inc. | Reduce -39.9% | 3.63% | +0.05 |
| NKTR Nektar Therapeutics | Reduce -2.9% | 0.66% | +0.17 |
| INSM Insmed Inc. | Reduce -58.2% | 4.00% | +0.27 |
| GH Guardant Health Inc. | Reduce -25.0% | 3.88% | +0.32 |
| DYN Dyne Therapeutics Inc. | Reduce -12.2% | 4.22% | +0.50 |
Portfolio Buys Q1 2024 → Q2 2024
| IMVT Immunovant Inc. | Add +484.5% | 2.27% | +1.82 |
| ARGX Argenx SE - ADR | Add +33.3% | 5.14% | +1.74 |
| TGTX TG Therapeutics Inc. | New | 1.52% | +1.52 |
| AXSM Axsome Therapeutics Inc. | Add +42.0% | 4.45% | +1.46 |
| NRIX Nurix Therapeutics Inc. | Add +33.1% | 2.49% | +1.22 |
| APLS Apellis Pharmaceuticals Inc. | Add +150.0% | 2.86% | +1.17 |
| IONS Ionis Pharmaceuticals Inc. | Add +45.6% | 2.85% | +1.14 |
| GPCR Structure Therapeutics Inc. | Add +2266.9% | 1.11% | +1.06 |
| AMGN Amgen Inc. | Add +4.5% | 5.37% | +0.87 |
| CLYM Climb Bio Inc. | New | 0.83% | +0.83 |
| KRRO Korro Bio Inc. | New | 0.78% | +0.78 |
| ETNB 89BIO Inc. | New | 0.55% | +0.55 |
| INO Inovio Pharmaceuticals Inc. | New | 0.50% | +0.50 |
| PRAX Praxis Precision Medicines I | New | 0.48% | +0.48 |
| CNTX Context Therapeutics Inc. | New | 0.44% | +0.44 |
| DVAX Dynavax Technologies Corp. | Add +19.2% | 3.66% | +0.39 |
| VRNA Verona Pharma Ltd. | Add +25.5% | 1.73% | +0.25 |
| OLMA Olema Pharmaceuticals Inc. | Add +24.0% | 1.29% | +0.24 |
| KURA Kura Oncology Inc. | New | 0.24% | +0.24 |
| CYTK Cytokinetics Inc. | New | 0.21% | +0.21 |
| ITCI Intra-Cellular Therapies Inc. | Add +2.5% | 3.15% | +0.16 |
| ZURA Zura Bio Ltd. | Add +30.1% | 0.34% | +0.16 |
| EWTX Edgewise Therapeutics Inc. | New | 0.10% | +0.10 |
| ALEC Alector Inc. | Add +22.9% | 0.63% | −0.02 |
| SYRE Spyre Therapeutics Inc. | Add +44.8% | 1.23% | −0.09 |
| KYMR Kymera Therapeutics Inc. | Add +18.8% | 1.34% | −0.12 |
| NTLA Intellia Therapeutics Inc. | Add +14.0% | 3.21% | −0.12 |
| VRDN Viridian Therapeutics Inc. | Add +13.5% | 1.52% | −0.21 |
| FDMT 4D Molecular Therapeutics Inc. | Add +33.8% | 2.55% | −0.23 |
| EDIT Editas Medicine Inc. | Add +8.6% | 0.84% | −0.34 |
| PLRX Pliant Therapeutics Inc. | Add +3.9% | 1.92% | −0.55 |
| SWTX Springworks Therapeutics Inc. | Add +6.3% | 4.16% | −0.76 |
Options Activity Q1 2024 → Q2 2024
| ITCI Intra-Cellular Therapies Inc. | put | Sold out | 175,400 | $12.1Mbefore exit |
| NMRA Neumora Therapeutics Inc. | call | New | 180,500 | $1.8M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 66 | $6.8B | GH, IMVT, GPCR, PCVX, ALNY |
| Q1 2026 | 62 | $4.8B | GH, IMVT, TARS, PCVX, GPCR |
| Q4 2025 | 53 | $4.4B | IMVT, GH, GPCR, TARS, DVAX |
| Q3 2025 | 56 | $3.6B | GH, IONS, CYTK, AKRO, APLS |
| Q2 2025 | 65 | $3.1B | GH, IONS, PTGX, DVAX, INSM |
| Q1 2025 | 69 | $3.1B | ITCI, GH, DVAX, IMVT, PTGX |
| Q4 2024 | 61 | $2.7B | DVAX, GH, ITCI, IMVT, APLS |
| Q3 2024 | 69 | $3.1B | ARGX, DVAX, GH, APLS, IMVT |
| Q2 2024 | 67 | $3.3B | AMGN, ARGX, AXSM, DYN, SWTX |
| Q1 2024 | 65 | $3.5B | SWTX, AMGN, APGE, INSM, DYN |